en · de · es · pt
tb-500-notes.peptides6088.com › Info › Detection, Stability, And Regulatory Status — Evidence Review

Detection, Stability, And Regulatory Status — Evidence Review

By Editorial Desk · published 2025-09-17 · last reviewed 2025-10-13 · Info

Everything below concerns prohibited substance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.

Detection, Stability, and Regulatory Status

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Tb-500 at a glance

PropertyValueNotes
Analytical methodLC-MS/MSPreferred confirmatory technique
AppearanceWhite to off-white powderLyophilised form
SolubilityFreely soluble in waterAlso described in saline
Storage temperatureBelow -20 °C for powderShort-term refrigeration for solutions
Regulatory statusProhibited in sportListed under peptide hormones

Identity and Physical Form

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

Related pages on this site

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Handling, Stability and Analytical Detection

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Reference notes

== Static and dynamic modes == In the field of surface analysis, it is usual to distinguish static SIMS and dynamic SIMS. Static SIMS is the process involved in surface atomic monolayer analysis, or surface molecular analysis, usually with a pulsed ion beam and a time-of-flight mass spectrometer, while dynamic SIMS is the process involved in bulk analysis, closely related to the sputtering process, using a DC primary ion beam and a magnetic sector or quadrupole mass spectrometer. Dynamic secondary-ion mass spectrometry (DSIMS) is a powerful tool for characterizing surfaces, including the elemental, molecular, and isotopic composition and can be used to study the structure of thin films, the composition of polymers, and the surface chemistry of catalysts. DSIMS was developed by John B. Fenn and Koichi Tanaka in the early 1980s. DSIMS is mainly used by the semiconductor industry.

This refrigeration method cools a contained area by melting ice, by sublimating dry ice, or evaporating liquid nitrogen. A simple example of this is a portable cooler, where ice is poured over the items that need to be refrigerated, keeping them cool and insulated from heat. Regular ice maintains freezing temperatures, but not below the freezing point, unless salt is used to cool the ice down further (as in a traditional ice-cream maker). Mixtures of other solvents with coolants like water ice, dry ice, or liquid nitrogen are also used to make cooling baths for chemistry. Dry ice can reliably bring the temperature well below the freezing point of water, to as low as 195K.

==== Biomolecular mechanisms ==== Chronic use of amphetamine at excessive doses causes alterations in gene expression in the mesocorticolimbic projection, which arise through transcriptional and epigenetic mechanisms. The most important transcription factors that produce these alterations are Delta FBJ murine osteosarcoma viral oncogene homolog B (ΔFosB), cAMP response element binding protein (CREB), and nuclear factor-kappa B (NF-κB). ΔFosB is the most significant biomolecular mechanism in addiction because ΔFosB overexpression (i.e., an abnormally high level of gene expression which produces a pronounced gene-related phenotype) in the D1-type medium spiny neurons in the nucleus accumbens is necessary and sufficient for many of the neural adaptations and regulates multiple behavioral effects (e.g., reward sensitization and escalating drug self-administration) involved in addiction. Once ΔFosB is sufficiently overexpressed, it induces an addictive state that becomes increasingly more severe with further increases in ΔFosB expression. It has been implicated in addictions to alcohol, cannabinoids, cocaine, methylphenidate, nicotine, opioids, phencyclidine, propofol, and substituted amphetamines, among others. ΔJunD, a transcription factor, and G9a, a histone methyltransferase enzyme, both oppose the function of ΔFosB and inhibit increases in its expression. Sufficiently overexpressing ΔJunD in the nucleus accumbens with viral vectors can completely block many of the neural and behavioral alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB).

Sources: en.wikipedia.org

Reference notes

==== Agriculture ==== The most substantial human use of water is for agriculture, including irrigated agriculture, which accounts for as much as 80 to 90 percent of total human water consumption. In the United States, 42% of freshwater withdrawn for use is for irrigation, but the vast majority of water "consumed" (used and not returned to the environment) goes to agriculture. Access to fresh water is often taken for granted, especially in developed countries that have built sophisticated water systems for collecting, purifying, and delivering water, and removing wastewater. But growing economic, demographic, and climatic pressures are increasing concerns about water issues, leading to increasing competition for fixed water resources, giving rise to the concept of peak water. As populations and economies continue to grow, consumption of water-thirsty meat expands, and new demands rise for biofuels or new water-intensive industries, new water challenges are likely. An assessment of water management in agriculture was conducted in 2007 by the International Water Management Institute in Sri Lanka to see if the world had sufficient water to provide food for its growing population. It assessed the current availability of water for agriculture on a global scale and mapped out locations suffering from water scarcity. It found that a fifth of the world's people, more than 1.2 billion, live in areas of physical water scarcity, where there is not enough water to meet all demands.

During insulitis, the pancreatic islets are infiltrated by T lymphocytes, B lymphocytes, macrophages, and NK cells, with the difference from the human course of insulitis being that CD4 + T lymphocytes are markedly reduced and CD8 + T lymphocytes are almost absent. The aforementioned lymphopenia is the major drawback of this model. The disease is characterized by hyperglycemia, hypoinsulinemia, weight loss, ketonuria, and the need for insulin therapy for survival. BB Rats are used to study the genetic aspects of T1D and are also used for interventional studies and diabetic nephropathy studies. LEW-1AR1 / -iddm rats are derived from congenital Lewis rats and represent a rarer spontaneous model for T1D. These rats develop diabetes at about 8–9 weeks of age with no sex differences, unlike NOD mice. In LEW mice, diabetes presents with hyperglycemia, glycosuria, ketonuria, and polyuria. The advantage of the model is the progression of the prediabetic phase, which is very similar to human disease, with infiltration of islet by immune cells about a week before hyperglycemia is observed. This model is suitable for intervention studies or for the search for predictive biomarkers. It is also possible to observe individual phases of pancreatic infiltration by immune cells. The advantage of congenic LEW mice is also the good viability after the manifestation of T1D (compared to NOD mice and BB rats).

Joseph Nightingale (1813), "Bristol", Beauties of England and Wales, vol. 13, London: J. Harris, Somersetshire James Dugdale (1819), "Somersetshire: Bristol", New British Traveller, vol. 4, London: J. Robins and Co. John Evans (1828), The New Guide, or, Picture of Bristol (4th ed.), Bristol, OCLC 45137262, OL 13521980M "Bristol", Great Western Railway Guide, London: James Wyld, 1839, OCLC 12922212 "Bristol", Black's Picturesque Tourist and Road-book of England and Wales (3rd ed.), Edinburgh: Adam and Charles Black, 1853 John Parker Anderson (1881), "Gloucestershire: Bristol", Book of British Topography: a Classified Catalogue of the Topographical Works in the Library of the British Museum Relating to Great Britain and Ireland, London: W. Satchell William Clark Russell (1883). "Bristol". North-East Ports and Bristol Channel. Newcastle-upon-Tyne: A. Reid. hdl:2027/uc1.$b667579. How to See Bristol. Bristol: Arrowsmith. 1893. "Bristol", Great Britain (4th ed.), Leipsic: Karl Baedeker, 1897, OCLC 6430424 Charles Gross (1897). "Bristol". Bibliography of British Municipal History. New York: Longmans, Green, and Co. Francis Adams Hyett; William Bazeley (1897). Bibliographer's Manual of Gloucestershire Literature. Vol. 3: City of Bristol. Dallaway, James (1834). Antiquities of Bristow in the Middle Centuries: including the topography by William Wyrcestre, and the life of William Canynges. Bristol: Mirror Office. Published in the 20th century

Sources: en.wikipedia.org

Frequently asked questions

How is the peptide detected in samples?

The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.

How should the powder be stored?

Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.

Is it approved for medical use?

It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network